gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Melanoma antigen family A, 10

This gene is a member of the MAGEA gene family. The members of this family encode proteins with 50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are clustered at chromosomal location Xq28. They have been implicated in some hereditary disorders, such as dyskeratosis congenita. Alternative splicing results in multiple transcript variants. Read-through transcription also exists between this gene and the downstream melanoma antigen family A, 5 (MAGEA5) gene.[provided by RefSeq, Oct 2011] (from NCBI)
Top mentioned proteins: MAGE-4, NY-ESO-1, MAGE-1, POLYMERASE, CT2
Papers on MAGE-10
MAGEA10 gene expression in non-small cell lung cancer and A549 cells, and the affinity of epitopes with the complex of HLA-A(∗)0201 alleles.
Huang et al., Beijing, China. In Cell Immunol, Sep 2015
MAGEA10, a cancer/testis antigens expressed in tumors but not in normal tissues with the exception of testis and placenta, represents an attractive target for cancer immunotherapy.
Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Zhou et al., Shanghai, China. In Int J Clin Exp Pathol, 2014
(CD133-MAGEA4-/CD133-MAGEA4+/CD133+MAGEA4-/CD133+MAGEA4+: 65.6 months vs.51.5 months vs.32.2 months vs.19.8 months, P=0.000, CD133-NY-ESO-1-/ CD133+NY-ESO-1-/CD133-NY-ESO-1+/ CD133+NY-ESO-1+: 57.8 months vs. 55.7 months vs. 44.6 months vs. 28.5 months, P=0.000, CD133-MAGEA10-/CD133+ MAGEA10-/CD133-MAGEA10-/CD133+MAGEA10+: 66.2 months vs. 57.2
Cancer-testis and melanocyte-differentiation antigen expression in malignant glioma and meningioma.
Bruce et al., New York City, United States. In J Clin Neurosci, 2012
The following primers were analyzed for CTA: LAGE-1, NY-ESO-1, MAGE-1, MAGE-3, MAGE-4, MAGE-10, CT-7, CT-10, HOM-MEL 40, BAGE, and SCP-1; and for MDA: tyrosinase, gp100, MELAN-A/MART-1, and TRP-2.
Pattern of cancer/testis antigen expression in lung cancer patients.
Lee et al., Pusan, South Korea. In Int J Mol Med, 2012
In the 79 lung cancer tissues, MAGE-3 (42%) was expressed most frequently and followed by NY-SAR-35 (33%), NY-ESO-1 (30%), MAGE-1 (27%), CT-7 (20%), MAGE-4 (19%), LAGE-1 (16%), and MAGE-10 (14%).
MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin and urothelial malignancies.
Spagnoli et al., Basel, Switzerland. In Int J Cancer, 2011
High MAGE-A10 is associated with lung, skin and urothelial malignancies.
Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients.
Colleoni et al., São Paulo, Brazil. In Cancer Immun, 2007
The expression of MAGEA1, MAGEA2, MAGEA3/6, MAGEA4, MAGEA10, MAGEA12, BAGE1, MAGEC1/CT7, the GAGE family, LAGE-1, PRAME, NY-ESO-1, SPA17 and SSX1 was studied by RT-PCR in 15 normal tissues, a pool of 10 normal bone marrow samples, 3 normal tonsils and bone marrow aspirates from 6 normal donors, 3 monoclonal gammopathies of undetermined significance (MGUS), 5 solitary plasmacytomas, 39 MM samples (95% advanced stage) and the MM cell line U266.
Breast cancer is a promising target for vaccination using cancer-testis antigens known to elicit immune responses.
Murray et al., Southampton, United Kingdom. In Breast Cancer Res, 2006
CONCLUSION: More than two-thirds of breast cancers would be covered by a vaccine directed against just three CTAGs - CTAG1, BAGE1, and MAGEA10 - all of which are known to be targets of cytotoxic-T-lymphocyte responses.
Expression of cancer testis antigens in head and neck squamous cell carcinomas.
Zago et al., Ribeirão Preto, Brazil. In Head Neck, 2006
METHODS: On this basis, we evaluated by semiquantitative reverse-transcriptase polymerase chain reaction (RT-PCR) the expression of genes that code for tumor antigens (melanoma antigen-1 [MAGE-1], MAGE-4, MAGE-10, MAGE-12, B melanoma antigen, CTL-recognized antigen melanoma antigen (CT antigen 2) [LAGE], New York esophageal squamous cell carcinoma antigen (CT antigen 1) [NYESO-1], and preferentially expressed antigen of melanoma [PRAME]) in surgical samples of the tumors, margins, and lymph nodes (when present) from patients with a diagnosis of head and neck carcinoma.
Melanoma-associated antigens in esophageal adenocarcinoma: identification of novel MAGE-A10 splice variants.
Beer et al., Ann Arbor, United States. In Clin Cancer Res, 2004
This is the first report of these MAGE-A10 alternative splice sequences, and characterization of MAGE-A expression
[Expression of tumor-specific cancer/testis antigens in hepatocellular carcinoma].
Wang et al., Beijing, China. In Zhonghua Gan Zang Bing Za Zhi, 2003
OBJECTIVE: (1) To investigate the expression and gene diversity of the 7 major cancer/testis (CT) antigens, MAGE-1, MAGE-3, MAGE-4, MAGE-10, NY-ESO-1, SSX-2 and SCP-1, in hepatocellular carcinoma (HCC).
[Expression of two types of melanoma antigens in hepatocellular carcinoma].
Wang et al., Beijing, China. In Zhonghua Zhong Liu Za Zhi, 2001
OBJECTIVE: To investigate the expression of melanoma antigen MAGE-4 and MAGE-10 mRNA in Chinese human hepatocellular carcinoma (HCC).
cDNA and protein characterization of human MAGE-10.
Cerottini et al., Lausanne, Switzerland. In Int J Cancer, 1999
Several clones that encoded a protein recognized by antibody 6C1 contained a sequence identical to that of MAGE-10, another member of the MAGE-A gene family.
share on facebooktweetadd +1mail to friends